Escitalopram is More Effective for Anxiety Than Mirtazapine
For anxiety disorders, escitalopram should be your first-line choice over mirtazapine. Escitalopram has robust FDA approval and extensive evidence for generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, and OCD, while mirtazapine lacks FDA approval for any anxiety disorder and has only preliminary evidence 1.
Evidence Hierarchy
Guideline and FDA-Approved Indications
The Japanese Society of Anxiety and Related Disorders guideline specifically identifies escitalopram (along with fluvoxamine and paroxetine) as the SSRIs covered by national health insurance for social anxiety disorder treatment 2. This guideline recognition reflects established efficacy.
The FDA label confirms escitalopram is approved for GAD, with three 8-week placebo-controlled studies demonstrating statistically significant improvement on the Hamilton Anxiety Scale (HAM-A) beginning at Week 1 and continuing through all study visits 1. Escitalopram is the only medication between these two with actual FDA approval for anxiety disorders.
Direct Efficacy Data
For GAD specifically:
- Escitalopram 10-20 mg/day showed mean HAM-A score improvement of -11.3 versus -7.4 for placebo (p<0.001), with 58% response rate versus 38% placebo 3
- A 24-week relapse prevention study showed escitalopram recipients had 4.04 times lower risk of relapse than placebo 4
- Escitalopram 10 mg/day was more efficacious than paroxetine 20 mg/day in head-to-head comparison 5
For mirtazapine in GAD:
- Only one open-label, fixed-dose study (no placebo control) showed 79.5% response rate at 12 weeks 6
- A review acknowledges mirtazapine "may be effective" in anxiety disorders but explicitly states "large, well designed trials are needed to confirm these findings" 7
Clinical Algorithm
Start with escitalopram 10 mg/day for anxiety disorders:
- Begin at 10 mg/day (the FDA-approved starting dose for GAD) 1
- Expect onset of anxiety improvement within 1 week 3
- Can increase to 20 mg/day after 4 weeks if inadequate response
- Continue for at least 6 months after remission to prevent relapse 4
Consider mirtazapine only when:
- Escitalopram has failed or is contraindicated
- Patient has severe comorbid insomnia, poor appetite, or weight loss requiring treatment 8
- Patient has treatment-resistant depression WITH severe anxiety (GAD-7 ≥16) as add-on therapy 9
Important Caveats
Mirtazapine's niche: While inferior for primary anxiety treatment, mirtazapine shows specific advantages for biological rhythm symptoms (sleep, appetite) in depression 8. The MIR trial secondary analysis found mirtazapine added to SSRI/SNRI reduced anxiety only in patients with severe baseline anxiety (GAD-7 ≥16), with no benefit in mild anxiety 9. This suggests mirtazapine works better as augmentation in severe cases rather than monotherapy.
Tolerability: Escitalopram discontinuation rates due to adverse events were not significantly different from placebo (8.9% vs 5.1%) in GAD trials 3. Both medications are generally well-tolerated, but escitalopram's side effect profile (sexual dysfunction, initial activation) differs from mirtazapine's (sedation, weight gain) 1.
Elderly patients: Use escitalopram 10 mg/day maximum in elderly patients due to 50% increased half-life 1. Both medications carry hyponatremia risk in this population.
The evidence strongly favors escitalopram as first-line pharmacotherapy for anxiety disorders based on FDA approval, multiple placebo-controlled trials, and long-term relapse prevention data. Mirtazapine remains an off-label option with limited evidence, best reserved for specific clinical scenarios or augmentation strategies.